Skip to main content
. 2022 Oct 21;28(39):5750–5763. doi: 10.3748/wjg.v28.i39.5750

Table 3.

Univariate and multivariate predictors of overall survival > 12 mo among patients with immune checkpoint inhibitor colitis (n = 64)

Clinical variables
Univariate predictors
Multivariate predictors
OR
95%CI
P value
OR
95%CI
P value
Demographics
Age (yr) 0.96 0.92-1.01 0.103 0.93 0.88-0.99 0.023
Male 0.82 0.29-2.32 0.711
Female 1.22 0.43-3.44 0.711
Race
White 0.87 0.23-3.27 0.835
Black 1.00 0.90-1.34 0.996
Asian 0.54 0.07-4.10 0.550
Other 1.07 0.97-1.11 0.912
Type of malignancy
Melanoma 1.26 0.45-3.51 0.654
RCC 0.51 0.12-2.28 0.381
NSCLC 0.53 0.10-2.85 0.456
Sarcoma 2.38 0.25-22.65 0.451
Head and neck SCC 1.05 0.89-1.10 0.865
Other 5.33 0.62-45.68 0.127
Stage IV malignancy 0.60 0.11-3.26 0.554
Presence of high grade IMC 0.91 0.32-2.57 0.855
Type of immune checkpoint inhibitor
Ipilimumab plus nivolumab 0.95 0.31-2.88 0.922
Ipilimumab 0.98 0.25-3.77 0.974
Nivolumab 0.09 0.01-0.83 0.033 0.13 0.01-1.43 0.096
Pembrolizumab 2.74 0.78-9.58 0.114 3.46 0.84-14.19 0.084
Atezolizumab 1.74 0.17-17.73 0.641
Number of ICI infusionsa 0.28 0.04-1.82 0.183
Dose of ICI (mg/kg) 1.88 0.36-9.83 0.457
Prior ICI use 0.46 0.12-1.80 0.265
Medical history
Non-liver, non-upper GI diseaseb 1.67 0.51-5.49 0.397
Personal history of autoimmune diseaseb 0.78 0.26-2.31 0.648
Family history of autoimmune diseaseb 0.93 0.20-4.29 0.922
Prior immune-enhancing therapyb 0.55 0.03-9.23 0.678
Prior interferon-g therapy 1.00 0.99-1.10 0.976
Vitamin D use 2.45 0.80-7.46 0.116 2.77 0.75-10.20 0.124
Smoking (current or prior) 1.66 0.59-5.65 0.334
NSAID use 2.55 0.49-13.16 0.265
Any vaccine 5.33 0.62-45.68 0.127
Flu vaccine 1.46 0.26-8.19 0.668
Pneumonia vaccine 1.00 0.99-1.05 0.995
Other vaccine 1.00 1.00-1.01 0.941
Weight at start of ICI (kg) 1.02 0.98-1.05 0.329
Medications
Steroid at start of ICI 0.98 0.25-3.77 0.974
Steroid duration (d) 1.00 1.00-1.01 0.736
Infliximab use 2.55 0.49-13.16 0.265
Vedolizumab use 1.00 1.00-1.01 0.936
a

Number of infusions of immune checkpoint inhibitor prior to immune checkpoint inhibitor-mediated colitis diagnosis (cases) or total (controls).

ICI: Immune checkpoint inhibitor; IMC: Immune checkpoint inhibitor-mediated colitis; SD: Standard deviation; RCC: Renal cell carcinoma; NSCLC: Non-small cell lung cancer; SCC: Squamous cell carcinoma; irAE: Immune related adverse event.